Try our Advanced Search for more refined results
Life Sciences - October, 2014
302 articles
- Herbalife Pays $15M To End 'Pyramid Scheme' Class Action
- 11th Circ. Rejects ERISA Claim Against Stiefel Labs
- Pfizer Ducks End-Payors' Lipitor Antitrust Claims
- AstraZeneca Slams Actavis With IP Suit Over Diabetes Drug
- 4 Cos. Raise $1.2B As US IPO Market Warms Back Up
- Sanofi's Duty To Detail FDA Concerns Key To Lemtrada Cases
- HHS Watchdog Details 2015 Plans To Scrutinize Medical Billing
- Consumer Group Takes Stem Cell Patent Fight To High Court
- 7th Circ. Casts A Wary Eye On Supplement Labeling Deal
- Actavis, NY AG Spar Over Antitrust Suit Injunction Bid
- Atossa Beats Claims It Duped Investors In $4M Offering
- 8 Ballot Measures Attorneys Will Be Watching
- Recall Or Enhancement? Read These Medical Device Rules
- Eli Lilly, Takeda Plan Appeal Of $37M Actos Ruling
- BMS, Sanofi Get Gene Patent Partially Invalidated In IP Suit
- Insurer On The Hook For Stryker Defect Claims, Judge Rules
- Merck Unit Says Fed. Circ. Erred In AllPure Patent Ruling
- SEC Hits InterMune Exec With Insider Trading Suit
- Life Sciences Groups Assail SF's Drug 'Take-Back' Plan
- 9th Circ. Revives Amgen ERISA Suit After High Court Remand
- Anemia Biotech FibroGen Readies For $124M IPO
- Rhythm Drops $86M IPO Plan After Actavis Deal
- Convicted Ex-Pfizer Manager Won't Testify In Off-Label Suit
- 11th Circ. Sends Trade Secret Dispute To Arbitration
- Jones Day Adds Ex-Womble Carlyle Tobacco Litigator
- New Guidelines Suggest A Friendlier European Patent Office
- GSK, Apexus Escape Drug Discount Antitrust Suit
- Law360 Names Most Feared Plaintiffs Firms Of 2014
- Apotex Wants Sanctions In Generic-Lipitor Labeling Suit
- Hospitals Decry Genentech's Cancer Drug Delivery Overhaul
- Biomet Pays $6M To End FCA Suit Over Bone-Growth Device
- Sens. Say Adding Ebola To FDA Program May Hasten Vaccine
- Teva Tells 3rd Circ. Other Rulings Back Lamictal Dismissal
- Fed. Circ. Won't Revive Expired Harvard Mice-Testing Patent
- Ex-Patent Rights Holders Want $20M Skin Drug Suit Revived
- HHS Looks To Existing Procurement Tool For Ebola Drugs
- Vinson & Elkins Nabs Litigators From Fenwick, Morgan Lewis
- FDA's Drug Risk Promo Proposal Slammed By All Sides
- Pa. Superior Court Urged To Nix $15M In Topamax Verdicts
- Cooley Leads Breast Implant Maker Sientra In $75M IPO
- Gov't Contractor Indicted For Alleged $116M Drug Return Plot
- Biosig Says Patent Is Valid Under New High Court Standard
- Minority Powerbrokers Q&A: Marshall Gerstein's Rin-Laures
- A Look At The First Ebola-Related Securities Lawsuit
- SEC Probes CMS In Stock Info Leak Investigation
- Allergan Says Ackman's Valeant Vote Would 'Gut' Protections
- Columbia Agrees To $9M Deal In Federal AIDS Grant FCA Row
- Actos Ruling Sets Up Appellate Clash Over Punitives Ceiling
- Illumina DNA Sequencing Patent Nixed In AIA Review
- Medicines Co. Beats Mylan In Generic-Angiomax Fight
- Amgen Spurns Breakup, Dusts Off $2B Buyback Plan
- Pfizer Says Lipitor Buyers Shouldn't Get To Redo Antitrust Suit
- Titan Of The Plaintiffs Bar: Mark Rifkin
- Kirkland Reps GTCR In Strategic Devicor Exit
- Covington Snags Ex-Norton Rose Fulbright Antitrust Chief
- Pfizer Keeps Market Guessing On M&A Moves As Earnings Rise
- A Close Look At The First 2 Post-Grant Review Petitions
- Acorda Ditches Apotex's Zanaflex False Ad Suit
- Fed. Circ. May Fill In Blanks On New Indefiniteness Rule
- $9B Takeda, Eli Lilly Actos Damages Slashed To $37M
- Fera's Injunction Claim Axed In $100M Trade Secret Suit
- Calif. Med Tech Co. Sets Terms For $100M IPO
- Biotech Co. Misled Investors About Role In Ebola Drug: Suit
- Looking At Lanham Act Claims Against Drug Cos. Post-Pom
- PE-Backed INC Research Aims To Raise Up To $150M In IPO
- Fujifilm Scoops Up Vaccine Maker As Ebola Crisis Worsens
- Allergan Decries Ackman's Smear Campaign Allegations
- Use Social Media For Legal Service Only As A Last Resort
- Valeant Could Hike Allergan Offer To $200-Plus Per Share
- Edwards IP Team May Join Mintz Levin Due To Merger
- Liberty Medical Strikes Deal Trimming $160M Medicare Claim
- NJ Diagnostic Co. Takes Merck Licensing Row To High Court
- US Urged To Pursue Contact Lens Antitrust Case
- Verinata's Fetal Test Patent Survives AIA Review On All Claims
- Nature's Bounty Duped Elderly Into Buying Gingko Biloba: Suit
- Hikma Gets FDA Warning After Portugal Facility Review
- 5 Ditch IPO Plans This Week As Markets Continue Volatility
- 4 Things To Watch As FDA Flexes New Inspection Powers
- Eli Lilly Gets AIA Reviews Of Institute's Fibrosis Patent
- Ex-BNY Mellon Manager Admits Tipping Scheme
- Shire Looks To Sink $1.5B AbbVie Termination Fee Into M&A
- Coherus Seeks IPO Raising $108.6M To Fund New Drugs
- New Restrictions On Int'l Trade In Genetic Resources
- Surprise Verdict In Hip Implant Trial Gives J&J The Edge
- Pfizer Unveils Mammoth $11B Buyback Program
- FDA Should Nix Drug Risk Proposal, Advocacy Group Says
- Teva Sues Chicago To Block Painkiller FOIA Disclosure
- San Francisco Reintroduces Drug 'Take-Back' Proposal
- Bankrupt Vitamin Maker Natrol Gets Nod For Nov. Auction
- FDA Clarifies Oversight Exception For Stem Cell Procedures
- Jury Clears J&J In 1st Bellwether Over Pinnacle Hip Implant
- Scientists Can't Shake $10M Gov't Contract Fraud Charges
- Pfizer's Cancer Drug Patent Withstands Mylan Challenge
- Grunenthal Dodges Thalidomide Suit In Spain
- Lupin, Amneal Lose Bid To Reverse Birth Control IP Ruling
- Bard Says Expert Can't Switch Sides In Pelvic Mesh MDL
- Reed Smith Hatches Global Ebola Task Force
- Biotech IPO Market Hits Turbulence As Several Price Low
- Deals Rumor Mill: Apollo Global, Advent, Sterigenics
- Ropes & Gray Sued By Drugmaker Over Patent Filing Blunder
- Effexor Buyers Want Another Chance In Antitrust Suit
- Glaxo Eyes IPO For HIV Unit As Part Of Restructuring Plan
- Nexium Jury Hears From Walgreen Exec On Generics
- ITC Agrees To Review Construction Of Sleep-Aid Patents
- OIG Remains Focused On Pharmaceutical Copayment Coupons
- Mylan Signals $5.3B Abbott Inversion On Track After Tweaks
- New Jurisdictional Issues When Moving To Quash A Subpoena
- Actavis Wins Bid To Keep Parts Of Antitrust Suit Under Seal
- DePuy Hip Implant Bellwether Trial Heads To Jurors In Texas
- OIG Finds Flaws In FDA's Cybersecurity Protections
- Pfizer Fights 'Do-Over' Of Plaintiff Experts In Zoloft MDL
- Viamet Gets $60M In Private Financing After Nixing IPO
- Deals Rumor Mill: Actavis, Siemens, Yahoo
- Titan Of The Plaintiffs Bar: Mark Lanier
- Senate Shake-Up Would Breathe New Life Into ACA Battles
- Nexium Jury Told Drug Cos. Wheeled-And-Dealed With Patent
- Nexium Pay-For-Delay Jury Told Size Of Settlement Is Key
- Molecular Partners Hits Brakes On IPO In Shaky Market
- Avandia User's Warranty Violation Suit Flops In 3rd Circ.
- FDA Finalizes Stance On Obstructed Pharma Inspections
- Special Master To Helm Walgreen Fee Fight In Pfizer MDL
- AbbVie Launches $5B Buyback After Failed Deal
- Ackman Says Allergan CEO Oversaw Valeant Smear Campaign
- GSK Bribery Conviction Signals Increased Risks In China
- Full Fed. Circ. Won't Review BMS Hepatitis Drug Patent Ruling
- Tech Giants Attack ITC's Patent Ruling On Digital Data
- TPP Catches Flak From Aussie Pols As Talks Forge Ahead
- Firsthand Knowledge Needed To Clear FCA Bar, 3rd Circ. Rules
- Device Makers Find Little Clarity In FDA Recall Guidance
- Atty Dodges Sanctions For 'Manic' Behavior At Fosamax Trial
- GE Can't Escape $5M Omniscan Verdict, 6th Circ. Says
- Pashman Stein Wins Rehearing Of Nostrum Fee Battle
- Amgen, CVS Units Hit With Suit Over Arthritis Drug Shipping
- Deals Rumor Mill: Adidas, Allergan, Sigma-Tau
- Dr. Reddy's Settles On Eve Of Nexium Pay-For-Delay Trial
- Cooley Steers Breast Implant Maker Sientra's IPO Plans
- Strong Valeant Earnings Buoy Talk Of Heftier Allergan Bid
- Fed. Circ. Slams Fee-Shifting Requirement In Pfizer IP Suit
- Random Selection Is Best For MDL Bellwether Trials
- Shire Loses CFO Following Failed $55B AbbVie Merger
- Takeda Urges Pa. Judge To Strike $2M Actos Cancer Verdict
- Actavis Aims To Shed Some Manhattan RE After Forest Buy
- Chattem Fights Class Cert. In Mouthwash Class Action
- Lawmakers Urge HHS To Combat Rising Generic-Drug Prices
- 5 IPOs Aim To Draw $450M In Coming Week
- Lannett Seeks Sanctions After Price-Fixing Suit Dropped
- First Actos Bladder Cancer Suit In W.Va. Goes To Trial
- CMS Launches New Open Payments Search Tool
- Taxation With Representation: Andrews Kurth, Jones Day
- 3rd Circ. Revives Genaera Investor Suit Over Asset Sales
- Covidien Earns Injunction Against J&J Unit's Ultrasonic Shears
- Hi-Tech Execs Want Out Of Jail After Recall
- Enviros Ask FDA To Ban 2 Food Packaging Chemicals
- Post-Firing Evidence Can Be A Potent Limit On Bias Damages
- What Litigators Can Learn From Novelists
- WikiLeaks Sparks Outcry With Release Of TPP Draft IP Text
- Ex-Siemens Patent Atty Indicted Over $2.5M Kickbacks Fraud
- Advocates Urge Fed. Circ. To Curtail ITC Digital Data Ruling
- GSK Dodges Claims Over Thalidomide Birth Defects
- FDA Naming Delay Cut Short Exclusivity, Drugmaker Says
- Deals Rumor Mill: PolyOne, Allergan, Wizz Air Holdings
- Kirkland Snags Lead BP Deepwater Litigation Trial Counsel
- J&J's Ethicon Fights $3M Verdict In Pelvic Mesh Trial
- Wilson Sonsini Grows In Delaware With Wilmington Office
- $55B AbbVie Deal Collapse Boosts Anti-Inversion Campaign
- Becton, Bard Trade Secrets Thief Gets 18 Months
- 3 Things To Watch Out For In Nexium Pay-For-Delay Trial
- One Biopharm Nixes IPO Plans As Second Makes Rocky Debut
- Ranbaxy To Pay $40M To Settle Texas Medicaid Fraud Case
- A-Rod's Purported Supplier Pleads Guilty To Drug Charges
- The 4 Hottest Sectors For IPOs Right Now
- The Learned Intermediary Doctrine: A Historical Review
- AbbVie Scraps $55B Shire Inversion After Treasury Crackdown
- If High Court Reverses Teva, Litigation Costs May Increase
- High Court Appears Split On Claim Construction Deference
- Investors Knock SAC's Bid To Cut Racketeering Claims
- Generic Drug Cos. Seek Federal Preemption Of Reglan Claims
- Deals Rumor Mill: ConvaTec, Vodafone, French Gov't
- Organon To Pay $31 Million Over FCA Medicaid Allegations
- PTAB To Review Claims In Novartis' Dementia Patch Patents
- Forward Pharma Raises $220M In Year's Largest Biotech IPO
- Assessing FDA Powers After A Failed 510(k) Rescinding
- AbbVie Backpedals On Landmark Inversion After Rule Tweaks
- NJ Tax Court Won't Revisit $3M Elan Assessment
- 9th Circ. Critical In Growing Class Ascertainability Fight
- Ex-Merck Analyst Charged With Insider Trading
- Supreme Court Passes On Medtronic's Noninfringement Win
- Deals Rumor Mill: Sysco, GlaxoSmithKline, Providence Equity
- ACA Spurs Feds To Rethink Anti-Kickback Policies
- Life Sciences M&A Keeps Rolling After Inversion Clampdown
- Biogenesis Co-Conspirator Pleads Guilty To MLB Doping
- Durata Investor Sues To Halt $675M Actavis Deal
- FDA Axes Controversial Plan On Med Device Safety Reports
- A Convergence Of Antitrust, Anti-Graft Enforcement In China
- Information Governance: A Missed Opportunity For Lawyers
- Med Tech Firm Steris Inks 1st Big Inversion Since Crackdown
- No Question Actavis Goes Beyond Cash, FTC's Wright Says
- AstraZeneca Facing Suit In Texas Over Seroquel Marketing
- Drug Company, Ex-Consultant Spar Over Noncompete Deal
- Off-Label Claims In Cephalon FCA Suits Trimmed By Judge
- FDA Approves New Gilead Hepatitis C Combination Drug
- Deals Rumor Mill: Actavis, Reliance Industries, Old Mutual
- Amberen Maker Blocked From Suing Class Action Plaintiff
- 2nd Circ. Weighs Sanction Doled To Bombastic Fosamax Atty
- Taxation With Representation: Fried Frank, Wachtell, Sullivan
- High Court Could Make It Harder To Reverse Patent Rulings
- CareMed Forks Over $10M To Settle FCA Phone Fraud Suit
- CAFA Removal Procedure At Center Stage In Dart Cherokee
- SEC Weighs Victims' Fund From $602M SAC Settlement
- J&J Unit Escapes Suit Over Birth Control Patch Clotting Risks
- Covington Atty Beats Back Trial Subpoena In Nexium MDL
- 2nd Circ. OKs Fujifilm's Post-Firing Evidence In Bias Suit
- NJ Court Nixes Jurisdiction Over Foreign Co. In Injury Suit
- PhRMA Launches New Suit Over 340B Orphan Drug Rule
- 3rd Circ. Sends Paxil Birth Defect Suit Back To Pa.
- ITC Asked to Reconsider Construction Of Sleep-Aid Patents
- Feds Challenge Ex-Orioles Player's Personal Benefit Defense
- Arnold & Porter in NY Gains Sheppard Mullin IP Partner
- BMS, Otsuka Say Abilify FCA Claims Don't Stick
- Auxilium Scraps Inversion Plan In Favor Of $2.6B Endo Offer
- FDA Takes Another Step Toward Regulating LDTs
- 4th Circ. Sets High Court FCA Agenda For 2014-15 Term
- Effexor Ruling Gives Plaintiffs Path Against No-AG Deals
- Calif. Judge Pares Par's False-Ad Suit, Citing Pom
- IBM, Oracle Prod Congress To Clarify FDA's Health IT Powers
- Deals Rumor Mill: Valeant, Shell, PT Pertamina
- Merck Can't Dodge $250M Sex Bias Class Action
- DLA Piper Snags Dentons Litigation Partner In Los Angeles
- Full Fed. Circ. Asked To Restore Apotex Patent
- Headhunting Firm Accuses Novartis Of $578K Breach
- J&J Pelvic Mesh Plaintiffs Want Cases Kept In Philly
- TTAB Axes Philips' Bid To Register Toothbrush Design Mark
- Is The Food GRAS Rule Silently Being Rewritten?
- A Primer On 'Bad Faith' In Federal Removal Jurisdiction
- Medtronic Infuse Injury Suit Revived By Md. Appeals Court
- Justices Question Their Powers In Class Action Removal Row
- GSK Investigating Corruption Allegations In UAE
- Pashman Stein Fights NJ Decision Freeing Nostrum From Fees
- Deals Rumor Mill: Swisscom, Waterland, Actavis
- Effexor Judge Says No-AG Deals Can Count As Payment
- Kimberly-Clark Ups Repurchase Goal To $2B After Spinoff
- Drugmakers Beat Doc Request In Diabetes Drug MDL
- Medtronic Pushes Tax Court For $581M Refund In IP Dispute
- 11th Circ. Pushback On Medical Guideline Litigation
- The State Of Umbrella Damages Under Calif. Antitrust Law
- King & Spalding Hires FTC Official For Antitrust Group In DC
- Sanofi Says It Revealed Overseas Bribery Claims To US
- Ex-Medtronic Worker Urges 9th Circ. To Revive OT Class
- Fed. Circ. Dismisses Lupin's Birth Control Cross Appeal
- Ex-Stiefel Exec Tells 11th Circ. His Stock Suit Was Timely
- Jurisdiction Bars 118 Philly Pelvic Mesh Suits, J&J Says
- Hi-Tech Execs To Remain Jailed Until Recall Is Complete
- Edwards Wildman Sees More London Exits Amid Merger Talks
- Covington Atty Says No Basis For Nexium Trial Subpoena
- High Court Won't Hear Omnicare Whistleblower's FCA Case
- Ex-Oriole Calls Feds' Insider Trading Indictment Flawed
- Michael J. Fox Foundation Sues Lab Over Spoiled Specimens
- $20M Knee Injury Dispute Could Rejigger Pa. Tort Law
- Bayer Rips Feds' Contempt Bid In Probiotics Promo Fight
- Herbalife Taps Ex-FTC Official As Global Compliance VP
- Actavis Tells High Court To Nix Lialda Patent Appeal
- Deal-Hungry Actavis Inks $675M Deal To Boost Disease Biz
- In-House Insights From KBR General Counsel Andrew Farley
- Takeaways From Chancery's Cornerstone Decision
- Skadden Steers Becton Dickinson To $12B CareFusion Buy
- Stryker Asks Justices To Hear Bed Patent Suit, Pending Teva
- Calif. Biotech Co. Dermira Debuts With $125M IPO
- Taxation With Representation: Cleary, Skadden, Baker
- Judge Says Actavis Not Limited To Cash Deals
- 4 Accutane Suits Against Roche Filed Too Late, Judge Rules
- Jury Hits Takeda With $2M In Damages In Philly Actos Case
- Deals Rumor Mill: Yahoo, Platform Specialty, Kellogg
- EU Opens In-Depth Probe Into $13B Zimmer-Biomet Deal
- Feds Target NJ Co. Over Tainted Ultrasound Gels
- Fed. Circ. To Eye Gene Patent Ruling's Reach In Myriad Case
- Nexium Buyers Point To Dow Ruling To Support Class Cert.
- Allergan's Hope For Rival Deal Dims Amid Investor Outcry
- CMS Payment Data Website May Stop Some FCA Claims
- Drug Labels Can Provide 'Specific Intent' For Inducement
- New Inversion Rules Force Medtronic Into Costlier Financing
- $2.7B Salix Inversion 1st Casualty Of Government Crackdown
- Covington Atty Takes Fire For Bucking Nexium Trial Subpoena
- Boston Scientific Hit With $34.6M Pelvic Mesh Judgment
- Sandoz Targets Chiesi Cardene Patents For PTAB Review
- Philly Jury Urged To Find Takeda Cancer Warnings Fell Short
- Lab Products Co. VWR Raises $536M In IPO
- Tyson Stops Use Of Antibiotics At Chicken Hatcheries
- ACA Payment Reporting Threshold Fuels Pharma Headaches
- Duane Morris Adds Corporate Star To Philly Office
- Stryker Can't Shake Claims Over Knee Implant Allergies
- FDA Finalizes Cybersecurity Guidance For Medical Devices
- Liberty Medical Unveils Plan For $47M Stalking Horse Sale
- BMS, Sanofi Lose Remand Challenge In Plavix MDL
- 7th Circ. Asked To Revive Ciba Contact Lens Injury Suit
- FDA Warns Hospira Over Injectable Drug Violations
- Philips Slammed With $467M Verdict In Masimo Patent Trial
- AbbVie Can't Keep AndroGel Death Suit Out Of State Court
- Takeda Shared Actos Cancer Data, Ex-FDA Official Testifies
- Blank Rome Adds Generic Drugs Pro From Reed Smith
- Covidien Unit Escapes FCA Suit Over Off-Label Marketing
- 1 Mammoth Deal Helps 2 Firms Dominate September M&A
- 11th Circ. Weighs In On Duty To Disclose Merger Talks